摘要
肺癌是中国发病率和死亡率均排第1位的恶性肿瘤,其中非小细胞肺癌(NSCLC)约占肺癌的85%。BRAF突变在NSCLC患者中的发生率约为1.5%~5.5%,而BRAF V600突变约占所有BRAF突变的30%~50%,BRAF突变患者整体预后较差。目前,关于BRAF突变NSCLC的临床研究探索越来越多,新药研发层出不穷,但国内尚无BRAF突变NSCLC诊疗相关的规范化共识。中国抗癌协会肺癌专业委员会专家组整合国内外BRAF突变相关的指南共识和现有的临床研究结果,结合我国BRAF突变的NSCLC诊疗经验,制定了中国晚期非小细胞肺癌BRAF突变诊疗专家共识,针对BRAF突变NSCLC的临床评估、诊疗流程、合理用药、不良反应管理等给出了详细建议,旨在为BRAF突变NSCLC的规范化管理和诊疗提供参考意见。
Lung cancer is the malignant tumor with the highest incidence and mortality rate in China,among which non-small cell lung cancer(NSCLC)accounts for about 85%.BRAF mutation occurs about 1.5%to 5.5%in NSCLC patients,while BRAF V600 accounts for about 30%to 50%of all BRAF mutations.The overall prognosis of patients with BRAF-mutation is poor.At present,there are many clinical trials on BRAF-mutation NSCLC and new drugs constantly emerging.However,there is no standardized consensus on the diagnosis and treatment of BRAF-mutation NSCLC in China.The expert group of the Lung Cancer Professional Committee of the Chinese Anti-Cancer Association formulated this consensus by integrating foreign and domestic BRAF-mutation-related guidelines,consensus,and existing clinical trials,and combining with Chinese experts′clinical experience in the diagnosis and treatment of BRAF-mutation NSCLC.This consensus provides systematic recommendations for the clinical diagnosis and treatment process,rational drug choice,and adverse events management of BRAF-mutation NSCLC,aiming to provide reference for the standard of diagnosis and treatment of BRAF-mutation NSCLC.
作者
中国抗癌协会肺癌专业委员会
程颖
张力
赵媛媛
Lung Cancer Professional Committee of Chinese Anti-Cancer Association;Cheng Ying;Zhang Li(不详;Department of Oncology,Jilin Cancer Hospital,Changchun 130012;Department of Medical Oncology,Sun Yat-sen University Guangzhou 510060)
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
2023年第4期279-290,共12页
Chinese Journal of Oncology
作者简介
通信作者:程颖,Email:jl.cheng@163.com;通信作者:张力,Email:zhangli@sysucc.org.cn。
